Low-Dose Ethyl Alcohol BBB Opening for Targeted Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for opening the blood-brain barrier (BBB) are unsafe, unpredictable, and lack control, leading to uneven distribution of therapeutics and adverse effects, hindering the delivery of large molecular agents to the brain.
Innovation Solution
Intra-arterial administration of low-dose ethyl alcohol (EA) at 0.01%-5% v/v, diluted with purified water or 0.9% NaCl, induces a transient, reversible, and safe BBB opening, allowing controlled delivery of non-BBB permeable substances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hyperosmolar mannitol is used to open the BBB, then the BBB can be opened transiently to deliver medications into the brain, but the method causes severe negative impacts on regional delivery of therapeutics and unpredictable adverse effects such as seizures, brain embolism, catastrophic bleeds, and fatal brain edema
Solution Approach 1:
The patent changes the chemical parameter from hyperosmolar mannitol to ethyl alcohol, and adjusts the concentration parameter to low doses (0.01%-5% v/v). This parameter change transforms the mechanism from osmotic disruption to a safer, more controllable BBB opening method that reduces harmful effects while maintaining therapeutic delivery capability
Solution Approach 2:
The patent introduces ethyl alcohol as an intermediary substance to mediate the BBB opening process. This intermediary acts as a safer alternative to mannitol, providing the necessary BBB disruption function while minimizing adverse effects on brain tissue and improving regional therapeutic delivery
2Productivity
If hyperosmolar mannitol is used to open the BBB, then medications can be delivered into the brain, but the BBB opening is nonsspecific and takes place throughout normal brain tissue
Solution Approach 1:
The patent applies local quality by enabling site-specific BBB opening through ethyl alcohol administration. The BBB opening occurs locally at the target region rather than diffusely throughout the entire brain, allowing precise control over which brain areas receive therapeutic agents while sparing normal brain tissue
3Reliability
If NEO100 is used to open the BBB, then the BBB can be opened in a dose-dependent manner, but the suspended NEO100 in water solution causes random, haphazard, unhomogenized BBB disruption and leads to patchy, punctate, or uneven distribution of extravasated EB dye inside the brain tissues
Solution Approach 1:
The patent changes the chemical composition parameter from suspended NEO100 particles in water to ethyl alcohol in aqueous solution. This parameter change eliminates the suspension instability issue, providing a homogeneous, stable solution that produces uniform BBB opening without patchy or punctate disruption patterns
Solution Approach 2:
The patent achieves homogeneity by using ethyl alcohol, which is completely miscible in water, creating a uniform solution without suspended particles. This homogeneous composition ensures even distribution and consistent BBB opening effects throughout the target brain region, eliminating the patchy and punctate patterns associated with NEO100
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ethyl alcohol provides a homogeneous and predictable BBB opening, enabling safe and targeted delivery of therapeutics like antibodies and CAR T cells to the brain without significant adverse effects, restoring BBB function after 120 minutes.
Implementation Method 1
Since the concept of osmotic BBB opening was introduced in 1972, the hyperosmotic mannitol has been used in the clinic for decades as a vehicle to transiently open BBB
Data Source
AI summary
A method of inducing blood-brain barrier (BBB) opening for delivery of a non-BBB permeable substance to a brain of a subject includes the steps of: administering an ethyl alcohol at 0.01%-5% v/v and the non-BBB permeable substance via microcatheter to a target area of the brain leading from an intracerebral artery and inducing a homogeneous distribution of the non-BBB permeable substance in the target area. The ethyl alcohol reaches the target area to induce a transient and reversible BBB opening for about 120 minutes so that the non-BBB permeable substance can penetrate the BBB to reach the target area. The non-BBB substance includes a therapeutic agent, a diagnostic agent, or a prophylactic agent. The use of low concentrations of ethyl alcohol allows the BBB to be restored to normal without causing significant harmful effects.